[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkin39s-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkin39s-lymphoma":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100590778","evaluation-of-skin-tests-in-biotherapy-allergies-100590778",false,"NCT06971848","Evaluation of Skin Tests in Biotherapy Allergies","ETCABIO","Inclusion Criteria :\n\n* Patient treated with one of the biotherapies under study (Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg, Cemiplimab 3500 mg) and who has received at least two injections of the biotherapy without suspected allergic side effects.\n* Subjects covered by or having the rights to medical care assurance\n* Written informed consent obtained from subject\n* If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed).\n\nExclusion Criteria:\n\n* Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests.\n* Poor understanding of the French language\n* Pregnancy, breastfeeding\n* Persons in detention by judicial or administrative decision\n* Person admitted to a health or social establishment for purposes other than research\n* Person subject to a legal protection measure",true,"ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases. In recent years, these biotherapies have notably emerged in the treatment of cancers and hematologic disorders. As such, most patients with cancers or hematologic diseases will likely receive a biotherapy as part of their care pathway.\n\nThese biotherapies are associated with various side effects, including hypersensitivity or allergic reactions, which are often poorly characterized in clinical trials. These reactions manifest as symptoms without specific dermatologic or allergologic semiology (such as itching, erythema, shortness of breath, sometimes digestive issues, or discomfort, and in some cases, an anaphylactic reaction).\n\nUnlike other treatments, such as antibiotics and neuromuscular blockers, there are currently no guidelines on the concentrations to use in skin tests for biotherapies. We propose conducting prospective clinical research to scientifically establish the concentrations to be used when investigating hypersensitivity to a biotherapy, in line with best practice recommendations for drug skin testing.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","Melanoma Neoplasms","Small Cell Bronchial Carcinomas","Bronchial Carcinoma","Pleural Mesothelioma","Hodgkin's Lymphoma","Chronic Lymphocytic Leukemia","Follicular Lymphoma","Myeloma","AL Amyloidosis","Hepatocarcinoma","Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Heart Cancer","Cholangiocarcinoma","Colorectal Adenocarcinoma","RECRUITING","2026-06-17",{"date":46,"type":47},"2026-06-18","ACTUAL",{"date":44,"type":47},{"date":50,"type":21},"2028-07",{"name":52,"class":53},"University Hospital, Angers","OTHER_GOV",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":54},"100604292","evaluation-of-chemotherapy-induced-cognitive-disorders-during-the-treatment-of-hematological-malignancies-100604292","NCT07147621","Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies","HematoBrain","Inclusion Criteria:\n\n* Patient group inclusion criteria:\n\n  * adult patient with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma;\n  * patient receiving a fixed-duration first-line chemotherapy;\n  * patient affiliated or beneficiary of a social security scheme; .signed inform consent form.\n* Control group inclusion criteria:\n\n  * adult;\n  * patient's relative (spouse, brother, sister, friend, etc.);\n  * less than 5 years of difference with the patient;\n  * same educational level (\\\u003C baccalaureate\u002Fhigh school degree, baccalaureate\u002Fhigh school degree level, 2-year university degree, \\> 2-year university degree);\n  * person affiliated or beneficiary of a social security scheme;\n  * signed informed consent form\n\nExclusion Criteria:\n\n* Patient group exclusion criteria:\n\n  * no patient's relative for the control group;\n  * known or suspective cognitive disorders prior to chemotherapy;\n  * history of severe neurological or psychiatric disorders (e.g., severe depression); .previous chemotherapy;\n  * previous brain radiotherapy;\n  * ongoing treatments affecting cognition;\n  * patient unable to read;\n  * patient not speaking French;\n  * person deprived of liberty by judicial or administrative decision;\n  * person under forced psychiatric care;\n  * person under legal protection measures;\n  * person unable to express consent; .pregnant or breastfeeding woman.\n* Control group exclusion criteria:\n\n  * known or suspected cognitive disorders;\n  * history of severe neurological or psychiatric disorder (e.g., severe depression); .previous chemotherapy;\n  * previous brain radiotherapy;\n  * ongoing treatments affecting cognition;\n  * person unable to read;\n  * person not speaking French;\n  * person deprived of liberty by judicial or administrative decision;\n  * person under forced psychiatric care;\n  * person under legal protection measures;\n  * person unable to express consent;\n  * pregnant or breastfeeding woman.\"",{"count":63,"type":21},120,"OBSERVATIONAL","Chemotherapy-induced cognitive disorders, such as memory problems, slowness of execution, inability to concentrate, and language difficulties, are sequelae that occur in patients undergoing chemotherapy or who have received chemotherapy. These symptoms lead to a degradation of the patients' quality of life and can have a significant social and familial impact. They are most commonly described in solid oncology, particularly in patients with breast cancer. Data about patients with hematological malignancies are scarce, but they seem to show the same phenomenon as in solid oncology. Indeed, many chemotherapies are used both in hematology and solid oncology and may therefore cause similar effects on cognition. Additionally, due to their mechanism of action, some chemotherapies specifically used in hematology could induce cognitive disorders. Hematology-treated patients are probably also affected by these disorders and may consequently experience a reduced quality of life.\n\nThe objective of this study is to assess the changes in cognitive functions in patients receiving chemotherapy for the treatment of hematological malignancies, using neuropsychological tests and a self-administered questionnaire, compared to a control group, as well as their potential impact on quality of life, fatigue, anxiety, and depression.",[67,32,68],"Acute Myeloid Leukemia","Non-Hodgkin's Lymphoma","2026-03-03",{"date":71,"type":47},"2026-03-06",{"date":73,"type":47},"2026-02-26",{"date":75,"type":21},"2027-10",{"name":52,"class":53}]